Bayer AG’s consumer health business continues to recover with allergy/cold and dermatology categories driving total sales up 2.6%, adjusted for foreign exchange and portfolio changes, to €5.46bn ($6bn) in 2019, the German firm reported on 27 February.
Sales in the OTC allergy/cold segment, which includes the Claritin (loratadine) allergy and Afrin (oxymetazoline) nasal relief brands, grew 5% in the fourth quarter, adjusting for effects, while the dermatology sector that